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Abstract
Background: Visual disorders are common in Parkinson’s disease (PD) but their exact frequency and severity are
unknown. Good visual functioning is crucial for patients with PD, because of their need to compensate for loss of
automated motor control and their postural instability, forcing patients to guide their movements visually. Here, we
describe the study design of a cross-sectional, multi-centre study aiming to: (1) validate the Visual Impairment
screening questionnaire (VIPD-Q, which aims to identify PD patients who should be referred to an ophthalmologist
for further assessment); (2) study the prevalence of visual disorders in PD; (3) study the severity and clinical impact
of different types of visual disorders in PD; and (4) explore treatment options for ophthalmologic disorders in PD, as
a basis for future guideline development.
Methods: This study consists of two phases. In phase one, 750 PD patients and 250 healthy controls will be
recruited to complete the VIPD-Q. In phase two, a subgroup of responders (n = 100) (with the highest and lowest
scores on the VIPD-Q) will be invited for an extensive neurological and ophthalmological assessment. The in-depth
ophthalmologic examination will serve as the “gold standard” for validating the VIPD-Q. Moreover, these
assessments will be used to study associations between visual disorders and clinical presentation, in order to gain
more insight in their clinical impact.
Discussion: Our study will heighten the awareness of visual problems in PD and offers a robust starting point to
systematically approach this subject. In current daily practice, the association between visual problems and PD is far
from obvious to both patients and clinicians. Consequently, patients may not adequately report visual problems
themselves, while clinicians miss potentially treatable visual disorders. Routinely asking patients to complete a
simple screening questionnaire could be an easy solution leading to timely identification of visual problems,
tailored treatment, restored mobility, greater independence and improved quality of life.
Trial registration: Dutch Trial Registration, NL7421, Registered on 4 December 2018 – Retrospectively registered.
Keywords: Parkinson’s disease, Ophthalmology, Eye, Visual impairment, Non-motor symptoms, Screening
questionnaire, Survey
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disease in the developed world. The
disease is characterized by a broad range of motor and
non-motor symptoms [1]. Non-motor-symptoms include
widely recognised examples such as gastrointestinal
complaints, cognitive decline or autonomic dysfunction,
but also less well appreciated ones such as visual impair-
ment [2]. Visual problems can range from blurred vision,
diplopia, reduced colour and contrast vision to visual field
deficits, and sore, red, or fatigued eyes. Visual disorders in
PD can be caused by different pathological mechanisms
like retinal dopamine depletion or decreased dopamin-
ergic innervation of the visual cortex [3, 4].
Almost 80% of visual impairments are treatable or
preventable. But to achieve this, timely recognition is
obviously pivotal [5]. However, in the field of PD, the
presence of visual problems and the resultant visual im-
pairment has remained severely under-recognized, both
in research and in clinical practice. This is surprising,
since the impact of visual problems is particularly vexing
for patients with PD, because of their need to compen-
sate for loss of automated motor control and their pos-
tural instability, forcing patients to guide their
movements externally (and this include visual guidance)
[6]. For example, visual cues such as stripes on the floor
are commonly used in clinical practice to overcome
freezing of gait [2, 7, 8]. Not being able to see these
visual cues adequately may have an immediate impact
on functioning in daily life. Indeed, visual disorders
combined with postural instability and gait disability can
increase the risk of falls and fall-related injuries such as
hip fractures and head injuries [9, 10]. Other obvious
consequences of visual deficits in PD include problems
with driving and reading. Taken together, disorders of
vision can lead to reduced physical activity, greater
dependence, disability, injuries and reduced quality of
life [11–13]. Yet, the exact frequency, type and severity
of visual problems are unknown. The few prior studies
on this subject showed inconclusive results, in part due
to small samples or lack of a complete ophthalmologic
examination [14–16]. Since many of these disorders can
be treated effectively, educating patients and doctors
about them can help to improve quality of life of
patients with PD.
The current multicentre observational, cross-sectional
VIP study: “Visual Impairment in Parkinson’s disease” is
designed to promote knowledge about and recognition
of symptoms, signs and causes of disturbed vision in
people with PD. Our specific goals are to: (1) validate a
screening questionnaire that aims to identify PD patients
who should be referred to an ophthalmologist for further
assessment; (2) determine the prevalence and severity of
visual problems in PD; (3) study the impact of
ophthalmologic disorders on clinical functioning (in
particular on gait and balance control); and (4) explore
treatment options for ophthalmologic disorders in PD,
as a basis for future guideline development.
Methods/design
Here we present our two-phase study, shown in Fig. 1.
In phase 1, we aim to have the Visual impairment in
Parkinson’s Disease Questionnaire (VIPD-Q) completed
by at least 750 PD patients and 250 healthy controls. In
phase 2, a subgroup of responders (n = 100) will be in-
vited for an extensive neurological and ophthalmological
assessment. The study is performed at three study sites
(Radboud University Nijmegen Medical Centre, the
Netherlands; the Medical University Innsbruck, Austria;
and The OLVG hospital Amsterdam, the Netherlands).
Each centre obtained local ethical approval
(NL58535.091.16;AN2016–0181).The study will be
performed in accordance with the Declaration of Helsinki.
All participants have to give written informed consent
prior to participation. This study is registered in The Dutch
trial register: NTR 7663.
Phase 1: screening questionnaire
The VIPD-Q was developed by neurologists and oph-
thalmologists to detect a broad range of ophthalmologic
disorders in PD patients. It is based on an extensive lit-
erature study, previous questionnaires, and common and
disabling visual disorders in both PD patients and
healthy older people [2, 11, 13, 15, 17–34]. The
questionnaire includes 22 questions on visual problems,
plus a standard set of demographic data (Additional file 1:
Appendix 1). Answers are given on a 4-point Likert scale
ranging from “never have problems” to “daily problems”,
without possibility to give a neutral answer. As a second
step, we grouped the questions according to the anatom-
ical location of a visual disorder. These domains were
agreed upon by a consensus procedure involving three in-
dependent ophthalmologists (one from each study site).
They were asked to categorize the questions in four do-
mains (Table 1: ocular surface, oculomotor, intra-ocular
and optic nerve). Consensus was reached during a
meeting with the three ophthalmologists. Six questions
could not be categorized in one domain, but rather indi-
cate the involvement of more than one anatomical do-
main. The VIPD-Q is designed as a patient self-scoring
instrument and takes about 20min to complete.
The VIPD-Q is both available on paper and online (in
English, German and Dutch). We will distribute the
questionnaire using different strategies: (1) PD patients
visiting the neurologic outpatient clinics at the three
study sites (complete the questionnaire on site); (2) PD
patients receiving care in one of the participating centres
(will receive the questionnaire via post); and (3) PD
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Fig. 1 Flowchart of the study design. Here we present our two-phase study. In phase 1, at least 750 PD patients and 250 healthy controls will
complete the Visual impairment in Parkinson’s Disease Questionnaire (VIPD-Q). In phase 2, a subgroup of responders (n = 100) will be invited for
an extensive neurological and ophthalmological assessment
Table 1 Domains and corresponding questions with possible diagnosis
Domains Issues Possible diagnosis Question
Ocular surface lacrimal fluid, eyelids,
conjunctiva, cornea
dry eye disease, blepharitis,
blepharospasm, conjunctivitis,
low eye blink rate,
1: I have blurry vision, when I read or work on a
computer.
2: I have a burning sensation or gritty feeling in my
eyes.
3: I have mucus/slime or particles in my eyes or eyelids.
4: I have watery eyes.
Intra-ocular lens, uvea, macula,
retina
diabetic retinopathy, macular
degeneration, retinal detachment,
hypertensive retinopathy, micro-
vascular retinopathy, cataract,
refraction errors, glaucoma
5: When I read, some letters disappear.
6: Lines that should be straight, appear to be wavy or
blurred.
7: I won’t go out alone in the evening or at night
because my night vision is insufficient.
8: When I drive at night, the oncoming headlights
cause more glare than before.
Oculomotor eye movements,
binocular cooperation
strabismus, convergence
insufficiency, 3rd, 4th and 6th nerve
palsies, nystagmus, gaze abnormality
9: Quick movements are hard to follow with my eyes.
10: I have double vision.
11: I can read better with one eye closed.
12: I have trouble with depth perception. I find it hard
to say which one of two objects is closer.
Optic nerve optic nerve disease opticopathy, glaucoma (Mimics:
structural lesion, hemianopsia)
13: Colours seem to be paler than before.
14: I can’t read plain text on a coloured or grey
background.
15: I run into objects or people or feel that parts of my
visual field are missing.
16. I have problems with rapid changes of light
intensity. (For example, driving through a tunnel).
The Visual Impairment in Parkinson’s Questionnaire (VIPD-Q) has been divided in 4 domains as shown above. These domains were agreed upon by a consensus
procedure involving three independent ophthalmologists (one from each study site). Six questions of the questionnaire could not be categorized in one domain,
but rather indicate the involvement of more than one anatomical domain
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patients interested in research, having registered on a plat-
form for research and innovation in PD: www.parkinson-
next.nl (will receive the online questionnaire through e-
mail). Healthy controls will be recruited by asking partners
and family members of participating patients to also
complete the questionnaire.
Phase 2: neurological and ophthalmological assessment
Patient collective and recruitment From the responders
of phase 1, a sample of 100 patients will be invited for a
full clinical and ophthalmological assessment. Patients
will be selected based on their scores on the VIPD-Q
aiming to include 70 patients with and 30 patients
without visual impairment, which is operationally
defined as patients scoring the highest 30% or the
lowest 30% on the screening questionnaire, respect-
ively. Due to personnel capacity, a sample of 30 pa-
tients in the Netherlands (10 in the lowest 30% and
20 in the highest 30%) and 70 patients in Austria (20
in the lowest 30% and 50 in the highest 30%) will be
selected and invited for the clinical and ophthalmo-
logical assessment. The OLVG hospital only partici-
pated in phase 1 of this study. Inclusion and
exclusion criteria are described in Table 2. Selection
will start after at least 250 questionnaires have been
completed. (See Fig. 1).
Procedures and assessments
All assessments will be performed during regular medi-
cation use, preferably in an “ON-state”. The assessment
will start with obtaining demographics and medical
history. The neurological and ophthalmological assess-
ments consist of an extensive test battery (Table 3).
Neurological examination
PD symptoms and severity including non-motor symp-
toms will be measured using the Movement Disorders
Society Unified Parkinson’s disease Rating Scale (MDS-
UPDRS) [35]. The non-motor symptoms scale (NMSS)
[36] and the Parkinson’s disease questionnaire-39 (PDQ-
39- quality of life) [37] will be used to assess the full
spectrum of PD symptoms. Hand-eye coordination and
manual dexterity will be tested using the nine-hole peg
test [38]. Mood and cognition will be assessed by the
Montreal cognitive assessment (MoCA), the CLOX II
test and the geriatric depression scale (GDS).
Gait and balance
Performance tests measuring different aspects of gait
and balance will be performed. Walking velocity will be
tested under single and dual-tasking conditions [39, 40].
The patients will be instructed to walk a distance of 4 m
at self-preferred speed. The required number of steps
will be reported as outcome. The Timed-Up-and-Go-test
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Diagnosis of PD according to the UKPDSBB criteria Hoehn and Yahr Parkinson’s staging score≥ 4
The patient must be able and willing to give written informed
consent
Secondary cause of parkinsonism as detected by history
(e.g. drug-induced parkinsonism)
The patient must be willing to participate in all study related
activities and visits
Secondary cause of parkinsonism as detected by investigation
(e.g. vascular parkinsonism as detected by neuroimaging)
Age of onset Parkinson’s disease > 30 years Dementia according to DSM-IV
Stable doses of Parkinson medications ≥4 weeks Major depressive disorder according to DSM-IV
Current age ≥ 60 years Psychotic disorder(s) according to DSM-IV
Prior brain surgery (except deep brain stimulation)
Previous eye surgery (except phacoemulsification for cataract and artificial
lenses)
Blindness in 1 eye
Medication that influences normal visual function other than PD medication.
(Detailed information, please see Additional file 2: Appendix 2)
Systemic diseases that may cause eye problems (HIV, DM type I, type II if
the patient had ophthalmologic therapy and/or abnormalities at last screening)
Neurodegenerative diseases other than Parkinson’s disease
History of lesions near the optic chiasm or occipital cortex
Migraine
Inclusion and exclusion criteria of the Visual Impairment in Parkinson’s Disease study
Abbreviations: UKPDSBB United Kingdom Parkinson’s Disease Soeciety Brain Bank, DSM-IV Diagnostic and Statistical Manual of Mental Disorders IV, HIV human
immunodeficiency virus, DM type I Diabetes Mellitus type I
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(TUG) measures the basic functional mobility [41].
Freezing of Gait (FOG) is assessed by letting the patient
make a 360° turn with small steps (approximately 25% of
their own preferred step length) and walking fast with
short steps [42]. To test axial symptoms, tandem gait at
a self-preferred speed is recorded for at least 10
consecutive steps without a visual guiding line [43]. The
Single Leg Stance test (SLS) will be used to test static
balance and postural instability [43–46]. Finally, postural
stability will be recorded by the Pull-Test (item 3.12
MDS-UPDRS).
Ophthalmological assessment
Subjective assessment
Some of the ophthalmological assessments require
responses from the patient and are therefore defined as
subjective measurements. The outcomes are visual acu-
ity, visual field testing, contrast sensitivity, colour vision,
ocular motility, facial emotion recognition and the visual
function questionnaire (VFQ-25) concerning visual func-
tion. We start the assessment with measuring the best
corrected visual acuity at distance, by using the Early
Treatment of Diabetic Retinopathy Study (ETDRS) chart
at 6 m [47]. 20/30–20/60 is considered mild vision loss,
or near-normal vision, 20/70–20/160, moderate visual
impairment and 20/200–20/400 severe visual impair-
ment. This is followed by testing reading or near visual
acuity, tested with the Radner reading charts at 40 cm
distance [48]. Reading correction is applied if applicable.
The reading speed is scored in words per minute.
Possible visual fields deficits including problems in the
peripheral vision are tested with the Humphrey or Octo-
pus Automated Field Analyzer in a standardized design
(SITA STANDARD 30–2) and analyzed by an ophthal-
mologist [49]. To measure the ability to detect objects
at low contrast, we will measure the contrast sensitiv-
ity with the Pelli-Robson charts. This assessment con-
sists of letters arranged in groups with varying
contrast, from high to low. Scores are based on the
contrast of the last group in which two or three let-
ters were correctly read, this can be calculated in a
logarithmic contrast sensitivity score (CSS). In an eld-
erly population (above 60 years old) a CSS lower than
1.50 is considered as decreased contrast sensitivity in
[50]. Colour discrimination is the ability to distinguish
differences between shades of colours and is divided
in primary colours (green, red, blue and yellow) and
their axis (red-green, blue-yellow). To evaluate colour
vision pseudo-isochromatic plates with coloured dots
forming numbers (Ishihara plates) will be used as a
screening tool. As a second step the Farnsworth desa-
tured 15D hue test will be performed to evaluate
more subtle colour vision deficiencies. This task con-
sists of ordering 15 coloured caps over trays in an in-
cremental manner according to their hue. Colour
vision deficiency will be scored in type of colour defi-
ciency and in severity [51, 52].
The examination of ocular motility will be done by
an orthoptist. First, we look at eye follow movements,
to detect any gaze paresis, nystagmus or saccadic
intrusions. Moreover, patients will be asked if they
experience diplopia. Diplopia is more common when
Table 3 List of assessments
Outcome Ophthalmological Assessment
Subjective ophthalmological
assessment
Visual acuity ETDRS logMAR
Reading speed, near visual acuity Radner Reading Chart
Visual fields Humphrey field analyser 30–2,
Amsler grid
Contrast vision Low-contrast letter charts
(Pelli-Robson),
Colour vision Ishihara plates/Farnsworth Munsell
hue test (desaturated 15D)
Ocular motility Eye follow movements, Cover test
30 cm and 6 m, Prism test
(15 diopter), Eye-Tracking
Facial emotion recognition Emotion Recognition Inventory (ERI)
Visual function VFQ-25, Visual impairment screening
questionnaire
Objective ophthalmological
assessment
Lens opacity Slit lamp examination
Fundus appearance Color Fundusphotography (7-fields)
Corneal thickness Pachymetry
Intraocular pressure (Goldmann) tonometry
Tear production Schirmer’s test,
TearFilmBreakUpTime, eye blink rate
Anatomical changes of the retina
including thickness
Spectral-domain OCT (Heidelberg)
Retinal micro vascular changes Angio-OCT (Heidelberg)
Outcome Neurological assessment
PD-related disability and
impairment
MDS-UPDRS, Schwab & England
activities of Daily living, NMSS,
PDQ-39.
Gait and Balance Timed Up and Go test, Single Leg
Stance test, Gait Speed
(4 m walking), Dual tasking,
Freezing of Gait, Tandem gait
Hand-eye coordination 9 Hole Pegboard test
Cognitive function MoCA, CLOX
Mood GDS
List of study protocol assessments, divided in ophthalmological and
neurological assessment
Abbreviations: EDTRS Early Treatment of Diabetic Retinopathy Study, D diopter,
OCT optical coherence tomography, NMSS non-motor symptoms assessment
scale, PDQ-39 Parkinson’s Disease Questionnaire, MoCA [47], Montreal
Cognitive Assessment, CLOX, clock drawing test [48], GDS, Geriatric depression
scale [49], VFQ-25, visual functioquestionnaire [72, 73]
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there is pre-existent ocular misalignment, this is a de-
viation in the fusion mechanism of the eyes. We use
the alternate-cover test at 30 cm and 6 m distance
[53] to screen for this. Additionally, convergence in-
sufficiency can cause diplopia and is characterized by
an increased near point of convergence (NPC), de-
creased convergence amplitudes and an exodeviation
at near. NPC and exodeviation at near will be mea-
sured along a RAF near point rule (Royal Air Force
Rule), here we measure if patients can maintain single
vision, when trying to focus on an approaching sub-
ject. Healthy (young) individuals can avoid double vi-
sion until 6 cm in front of their nose. A NPC value
that is more than 10 cm from the bridge of the nose
is considered abnormal. Convergence amplitudes are
measured with a prism, while the patient focuses on
a target at near. In general, fusional convergence am-
plitudes of less than 20 prism diopters at near are a
sign of convergence insufficiency [54–56]. In addition,
we will use an exploratory Eye-Tracking set up with a
Tobii TX300 Eye-Tracker to measure ocular move-
ments and smooth pursuit. Furthermore, we investi-
gate visual and vocal emotion perception and
processing using the Emotion Recognition Index (ERI)
[57, 58]. This instrument assesses the ability of indi-
viduals to correctly infer target emotions from actor
portrayals of vocal and facial emotion expressions.
Objective assessment
Results of these tests will be obtained without receiv-
ing feedback from the patient and are therefore
objective measurements. The outcomes are changes in
the eyelids, conjunctiva, cornea, fundus, iris and lens
opacity, corneal thickness and intraocular pressure,
tear production, anatomical changes of the retina
including micro vascular changes. First, we examine
the eyelids and conjunctiva, followed by inspection of
the cornea, iris and using slit lamp examination. This
to detect for example blepharitis or conjunctivitis.
Lens opacity will be rated with the LOCSIII score,
this to evaluate and grade possible cataract [59]. After
pupil dilation with tropicamide 0,5% fundus photog-
raphy is captured. The same experienced ophthal-
mologist will inspect and grade all fundus images. We
will evaluate the macula, retina and vascular struc-
tures. This to detect possible presence of macular de-
generation, macular edema, vascular pathology,
peripapillary atrophy, retinopathy, optic nerve pallor
and to evaluate cup-to-disc ratio. A ratio greater than
0.5 may imply glaucoma or other pathology. Further-
more the thickness of the cornea will be measured with
pachymetry, this is important because it can mask an ac-
curate reading of the intraocular pressure(IOP). Moreover,
a reference range in PD is not known. Pachymetry will be
performed after applying local drops of anaesthetics.
Corneal thickness ranges between 500 and 575 μm in the
healthy population [60]. The IOP will be measured using
applanation tonometry (Goldmann tonometer), non-
contact tonometry is less reliable [61]. An eye pressure
higher than 18mmhg is considered higher than normal
and has an increased risk for glaucomatous damage of the
optic disc [62]. Complaints of the ocular surface are
mainly caused by affections of tear quality and quantity.
Tear film quality will be approached by the TearFilmBrea-
kUpTime (TFBUT), while the quantity of tears is will be
measured by the Schirmer test. TFBUT is recorded as the
time between a complete blink and the appearance of
the first randomly distributed dry spot, where a score
less than 10 s is considered abnormal [63]. The
Schirmer test measures the amount of fluid appearing
on the ocular surface within 5 min. For this, paper
strips are inserted into the lower fornix with (Schirmer II)
and without (Schirmer I) local anaesthesia, and the wet
distance is measured in millimetres. Less than 10mm is
considered abnormal and less than 5 is severe [26, 63, 64].
If the Schirmer test and/or TFBUT show lower-than-
normal results, the diagnosis “dry eye” or keratoconjuncti-
vitis sicca in case of clinical complaints is made. In Parkin-
son patients, a reduced eye blink rate EBR may add to an
ocular surface disease and dry eye symptoms The EBR is
defined as the number of eye blinks per minute measured
in a 3-min interval, less than 15 blinks per minute is
considered abnormal [26, 65]. Finally, optical coherence
tomography (OCT) will be performed to evaluate
pattern changes of the retina including the retinal
thickness [66–68]. Angio-OCT will be used to inspect
the micro vascular changes of the retina [69].
Statistical analysis plan
95% Confidence intervals, means, standard deviations
and frequency distributions will be calculated for all out-
comes. Nonparametric variables (age, disease duration,
LED, total score VIPD-Q) will be expressed as the
median, interquartile range (IQR), minimum, and
maximum. To compare groups, we will use the student’s
t-test for parametric continuous variables and the
Mann-Whitney U test for non-parametric continuous
variables. All analyses will be performed with SPSS 22.0
(SPSS Inc., IBM, Chicago, IL, USA).
To address the first study objective (validity of the
screening questionnaire), we will compare the results
of the VIPD-Q with the ophthalmological assessments
using analysis of intraclass correlation coefficient
(ICC), with Cohen’s kappa. The results of the
ophthalmological assessments will be categorized in
visual disorders within the domains of the VIPD-Q
(ocular surface, intra- ocular, oculomotor and optic
nerve). We hypothesize moderate to good correlation
Borm et al. BMC Neurology          (2019) 19:141 Page 6 of 9
(ICC > 0.5) between the scores on the domains based
on the ophthalmological tests and the scores on the
domains based on the screening questionnaire. We
will also address correlation for the total score. In
addition, we will calculate optimal cut-off points of the
domains and total score of the VIPD-Q using the receiver
operating characteristic (ROC).
For the second and third objective (determine the
prevalence and severity of visual problems in PD; impact
on clinical functioning), PD patients will be compared
with healthy controls using chi-square-tests for categor-
ical values (sex, education, co morbidity, visited ophthal-
mologist, visual aid, vision changes during the day,
difficulties with daily activities, impact on quality of life)
or Mann-Whitney U test for non-parametric continuous
variables (age, total score VIPD-Q, score per domain).
Furthermore, the relationship between falling, disease
duration, MDS-UPDRS, hand-eye dexterity, gait and bal-
ance tests, and visual problems will be assessed using
multiple linear regression analysis.
Data management
The certified data management system “Castor” will be
used Each patient will be coded with a unique patient
identification number. Personal patient information
(such as name and date of birth) is stored separately
from the research data. The key to the code is safe-
guarded by the coordinating researcher. Research data is
stored for 15 years and only accessible for members of
the research team.
Discussion
Numerous visual problems have been reported in
patients with PD. However, these problems appear to be
markedly under-recognized as well as undertreated, and
are also being poorly understood. Patients may not
adequately report ophthalmic problems themselves,
while clinicians frequently miss ocular disorders that in
many cases can be treated. This may result in a delayed
diagnosis and further deterioration of visual impairment.
Moreover, undertreated patients experience an unneces-
sarily high risk of falling and sustaining injuries. Previous
research has shown contradicting outcomes on the
prevalence and suggested pathology of eye problems in
PD [2, 11, 13, 70, 71]. The present VIP study is designed
to provide new insights into the field of visual function in
PD. Our theory-based screening questionnaire is designed
to timely detect visual problems and to heighten the
awareness of visual impairment in the PD population. It
may assist in earlier detection of visual symptoms and
thus help clinicians to select optimal diagnostic and thera-
peutically strategies. This could lead to improved patient
care and an improved quality of life for PD patients.
Trial status
The final protocol version is 3.0 and date April 2017.
This trial is currently recruiting participants. Recruit-
ment of phase 1 has started December 2016 and was
completed August 2018. Recruitment of phase 2 began
in May 2017. We expect the recruitment of phase 2 to
be complete by May 2019.
Additional files
Additional file 1: Screening questionnaire: Visual impairment in
Parkinson’s disease. VIPD-Q questionnaire original format. (DOCX 29 kb)
Additional file 2: Medication that influences normal visual function
other than PD medication. Commonly used drugs associated with eye
diseases, risk 1% or more [73]. (DOCX 12 kb)
Abbreviations
AUC: Area under the curve; CLOX: Clock drawing test; CSS: The logarithmic
contrast sensitivity score; D: Dioptre; DM type I: Diabetes type I; EBR: Eye
blink rate; ERI: Emotion Recognition Index; ETDRS: Early Treatment of
Diabetic Retinopathy Study; FOG: Freezing of gait; GDS: Geriatric depression
scale; ICC: Intraclass correlation coefficient; IOP: Intra-ocular pressure;
IQR: Interquartile range; LED: Levodopa equivalent dose; MDS-
UPDRS: Movement disorders society - Unified Parkinson’s Disease rating
scale; MoCA: Montreal Cognitive Assessment; NMSS: Non-motor symptoms
assessment scale; NPC: Near point of convergence; OCT: Optical coherence
tomography; OLVG: onze lieve vrouwen gasthuis (hospital); PD: Parkinson’s
disease; PDQ-39: the Parkinson’s disease questionnaire-39; RAF: Royal Air
Force Rule, near point rule; ROC: Receiver operating characteristic; SLS: Single
leg stance test; TFBUT: TearFilmBreakUpTime; TUG: Timed up and go test;
VFQ-25: Visual function questionnaire; VIP: Visual impairment in Parkinson’s
disease; VIPD-Q: Visual impairment in Parkinson’s disease questionnaire
Authors’ contributions
CB and MW participated in the neurologic and ophthalmological design,
coordination of the study and drafted the manuscript. FV and MP
participated in the design and coordination in the different study sites and
have been involved in revising the manuscript for important intellectual
content. DP, TT and IN participated in its design mostly the
ophthalmological part and have been involved in revising the manuscript for
important intellectual content. CH participated in the ophthalmological
design and has been involved in revising the manuscript for important
intellectual content. KS conceived of the study and participated in its design
and coordination and has been involved in revising the manuscript for
important intellectual content. AV participated in the neurologic part of the
design and has been involved in revising the manuscript for important
intellectual content. BB and WP conceived of the study and participated in
its design and coordination and has been involved in revising the
manuscript for important intellectual content. NV conceived of the study and
participated in its design and coordination. Furthermore, supervised the
design and critical revised the manuscript. All authors read and approved
the final manuscript.
Funding
This study is funded by a research grant from the Stichting Parkinson Fonds
(grant number 38000). These non-corporate funding organization has no role
in study design or conduct of the study, data collection, data analysis and
interpretation or manuscript preparation. The study protocol was peer
reviewed by the Stichting Parkinson Fonds.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analysed during the current study.
Borm et al. BMC Neurology          (2019) 19:141 Page 7 of 9
Ethics approval and consent to participate
The Medical Ethics Committee Arnhem-Nijmegen (NL58535.091.16) and
Innsbruck (AN2016–0181) approved the study. Written informed consent will
be obtained from all patients after detailed explanation of the procedures.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Neurology, Parkinson Center Nijmegen (ParC) Nijmegen,
Donders institute for Brain, Cognition and Behaviour, Radboud University
Medical Centre, PO Box 9101, 6500, HB, Nijmegen, The Netherlands.
2Radboud University Medical Centre, Department of Ophthalmology,
Nijmegen, The Netherlands. 3Department of Neurology, Medical University
Innsbruck, Innsbruck, Austria. 4Department of ophthalmology, Medical
University Innsbruck, Innsbruck, Austria. 5Department of Neurology, Onze
Lieve Vrouw Gasthuis (OLVG), Amsterdam, The Netherlands. 6Department of
Ophthalmology, Leiden University Medical Centre, Leiden, The Netherlands.
Received: 12 April 2019 Accepted: 13 June 2019
References
1. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints
precede Parkinson disease: the Rotterdam study. Arch Neurol.
2006;63(3):362–5.
2. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in
Parkinson’s disease. Vis Res. 2005;45(10):1285–96.
3. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson’s
disease. Brain. 2009;132(Pt 5):1128–45.
4. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on
the dysfunction of retinal dopaminergic circuitry in Parkinson’s disease.
Surg Radiol Anat. 1988;10(2):137–44.
5. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010.
Br J Ophthalmol. 2012;96(5):614–8.
6. Nonnekes J, Nieuwboer A, Hallett M, Fasano A, Bloem B. Compensation
strategies for gait impairments in Parkinson’ disease. JAMA Neurol. 2019.
7. Azulay JP, Mesure S, Amblard B, Blin O, Sangla I, Pouget J. Visual control of
locomotion in Parkinson’s disease. Brain. 1999;122(Pt 1):111–20.
8. Azulay JP, Mesure S, Amblard B, Pouget J. Increased visual dependence in
Parkinson’s disease. Percept Mot Skills. 2002;95(3 Pt 2):1106–14.
9. Wood BH, Bilclough JA, Bowron A, Walker RW. Incidence and prediction of
falls in Parkinson’s disease: a prospective multidisciplinary study.
J Neurol Neurosurg Psychiatry. 2002;72(6):721–5.
10. Rumalla K, Gondi KT, Reddy AY, Mittal MK. Association of Parkinson’s disease
with hospitalization for traumatic brain injury. Int J Neurosci.
2017;127(4):326–33.
11. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ.
Ophthalmologic features of Parkinson’s disease. Neurology.
2004;62(2):177–80.
12. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in
Parkinson’s disease and Parkinson’s disease dementia. Mov Disord.
2011;26(13):2387–95.
13. Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K.
Ophthalmological features of Parkinson disease. Med Sci Monit.
2014;20:2243–9.
14. Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of
spatial and chromatic processing deficits in Parkinson disease. Arch Neurol.
2002;59(8):1249–52.
15. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M.
Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s
disease. J Geriatr Psychiatry Neurol. 2006;19(1):36–40.
16. Ekker MS, Janssen S, Seppi K, Poewe W, de Vries NM, Theelen T, Nonnekes J,
Bloem BR. Ocular and visual disorders in Parkinson’s disease: common but
frequently overlooked. Parkinsonism Relat Disord. 2017.
17. Goldberg I, Hollows FC, Kass MA, Becker B. Systemic factors in patients with
low-tension glaucoma. Br J Ophthalmol. 1981;65(1):56–62.
18. Buttner T, Kuhn W, Klotz P, Steinberg R, Voss L, Bulgaru D, Przuntek H.
Disturbance of colour perception in Parkinson’s disease. J Neural Transm
Park Dis Dement Sect. 1993;6(1):11–5.
19. Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson’s
disease. J Pediatr Ophthalmol Strabismus. 1996;33(3):144–7.
20. Muller T, Kuhn W, Buttner T, Przuntek H. Distorted colour discrimination in
Parkinson’s disease is related to severity of the disease. Acta Neurol Scand.
1997;96(5):293–6.
21. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination
and contrast sensitivity in Parkinson’s disease. J Neurol Sci. 2000;172(1):7–11.
22. Hutton JT, Morris JL. Vision in Parkinson’s disease. Adv Neurol. 2001;86:279–88.
23. Muller T, Woitalla D, Peters S, Kohla K, Przuntek H. Progress of visual
dysfunction in Parkinson’s disease. Acta Neurol Scand. 2002;105(4):256–60.
24. Sprengelmeyer R, Young AW, Mahn K, Schroeder U, Woitalla D, Buttner T,
Kuhn W, Przuntek H. Facial expression recognition in people with
medicated and unmedicated Parkinson’s disease. Neuropsychologia.
2003;41(8):1047–57.
25. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic
Parkinson’s disease: a retrospective autopsy study. Lancet Neurol.
2005;4(10):605–10.
26. Tamer C, Melek IM, Duman T, Oksuz H. Tear film tests in Parkinson’s disease
patients. Ophthalmology. 2005;112(10):1795.
27. Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson
disease. Nat Rev Neurol. 2009;5(6):331–42.
28. Seichepine DR, Neargarder S, Miller IN, Riedel TM, Gilmore GC, Cronin-
Golomb A. Relation of Parkinson’s disease subtypes to visual activities of
daily living. J Int Neuropsychol Soc. 2011;17(5):841–52.
29. Armstrong RA. Oculo-visual dysfunction in Parkinson’s disease. J Park Dis.
2015;5(4):715–26.
30. Lin TP, Rigby H, Adler JS, Hentz JG, Balcer LJ, Galetta SL, Devick S, Cronin R,
Adler CH. Abnormal visual contrast acuity in Parkinson’s disease. J Park Dis.
2015;5(1):125–30.
31. MacAskill MR, Anderson TJ. Eye movements in neurodegenerative diseases.
Curr Opin Neurol. 2016;29(1):61–8.
32. Matlach J, Wagner M, Malzahn U, Schmidtmann I, Steigerwald F, Musacchio
T, Volkmann J, Grehn F, Gobel W, Klebe S. Retinal changes in Parkinson’s
disease and glaucoma. Parkinsonism Relat Disord. 2018:56, 41–6.
33. Ahn J, Lee JY, Kim TW, Yoon EJ, Oh S, Kim YK, Kim JM, Woo SJ, Kim KW,
Jeon B. Retinal thinning associates with nigral dopaminergic loss in de novo
Parkinson disease. Neurology. 2018;91(11):e1003–12.
34. McDowell SA, Harris JP. Visual problems in Parkinson’s disease: a
questionnaire survey. Behav Neurol. 1997;10(2):77–81.
35. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P,
Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society-
sponsored revision of the unified Parkinson’s disease rating scale (MDS-
UPDRS): scale presentation and clinimetric testing results. Mov Disord.
2008;23(15):2129–70.
36. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S,
Ruessmann A, Odin P, Macphee G, Stocchi F, et al. The nondeclaration of
nonmotor symptoms of Parkinson’s disease to health care professionals: an
international study using the nonmotor symptoms questionnaire. Mov
Disord. 2010;25(6):704–9.
37. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and
validation of a short measure of functioning and well being for individuals
with Parkinson’s disease. Qual Life Res. 1995;4(3):241–8.
38. Ruzicka E, Krupicka R, Zarubova K, Rusz J, Jech R, Szabo Z. Tests of manual
dexterity and speed in Parkinson’s disease: not all measure the same.
Parkinsonism Relat Disord. 2016;28:118–23.
39. Bootsma- van der Wiel A, Gussekloo J, de Craen AJM, van Exel E, Bloem BR,
Westendorp RG. Single versus dual task walking performance as predictor of
falls in the general population of oldest old. Results of the Leiden 85-plus
study. J Am Geriatr Soc. 2003;51:1466–71.
40. Mak MK, Pang MY. Parkinsonian single fallers versus recurrent fallers:
different fall characteristics and clinical features. J Neurol. 2010;257(9):1543–51.
41. Mak MK, Pang MY. Balance confidence and functional mobility are
independently associated with falls in people with Parkinson’s disease.
J Neurol. 2009;256(5):742–9.
42. Snijders AH, Nijkrake MJ, Bakker M, Munneke M, Wind C, Bloem BR.
Clinimetrics of freezing of gait. Mov Disord. 2008;23(Suppl 2):S468–74.
43. Borm C, Krismer F, Wenning GK, Seppi K, Poewe W, Pellecchia MT, Barone P,
Johnsen EL, Ostergaard K, Gurevich T, et al. Axial motor clues to identify
Borm et al. BMC Neurology          (2019) 19:141 Page 8 of 9
atypical parkinsonism: a multicentre European cohort study. Parkinsonism
Relat Disord. 2018;56:33–40.
44. Jacobs JV, Horak FB, Tran VK, Nutt JG. Multiple balance tests improve the
assessment of postural stability in subjects with Parkinson’s disease.
J Neurol Neurosurg Psychiatry. 2006;77(3):322–6.
45. Abdo WF, Borm GF, Munneke M, Verbeek MM, Esselink RA, Bloem BR. Ten
steps to identify atypical parkinsonism. J Neurol Neurosurg Psychiatry.
2006;77(12):1367–9.
46. Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, Janssen MJ,
Borm GF, Bloem BR, Verbeek MM. Ancillary investigations to diagnose
parkinsonism: a prospective clinical study. J Neurol. 2015;262(2):346–56.
47. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F 3rd. Detection of
diabetic macular edema. Ophthalmoscopy versus photography--early
treatment diabetic retinopathy study report number 5. The ETDRS research
group. Ophthalmology. 1989;96(6):746–50 discussion 750-741.
48. Maaijwee K, Mulder P, Radner W, Van Meurs JC. Reliability testing of the
Dutch version of the Radner Reading charts. Optom Vis Sci. 2008;85(5):353–8.
49. Landers J, Sharma A, Goldberg I, Graham SL. Comparison of visual field
sensitivities between the Medmont automated perimeter and the
Humphrey field analyser. Clin Exp Ophthalmol. 2010;38(3):273–6.
50. Mantyjarvi M, Laitinen T. Normal values for the Pelli-Robson contrast
sensitivity test. J Cataract Refract Surg. 2001;27(2):261–6.
51. Farnsworth D. Testing for color deficiency in industry. AMA archives of
industrial health. 1957;16(2):100–3.
52. Hardy LH. Standard illuminants in relation to color-testing procedures.
Arch Ophthal. 1945;34:278–82.
53. Thomas R, Braganza A, George T. Practical approach to diagnosis of
strabismus. Indian J Ophthalmol. 1996;44(2):103–12.
54. Shaunak S, O'Sullivan E, Kennard C. Eye movements. J Neurol Neurosurg
Psychiatry. 1995;59(2):115–25.
55. Danchaivijitr C, Kennard C. Diplopia and eye movement disorders.
J Neurol Neurosurg Psychiatry. 2004;75(suppl 4):iv24–31.
56. Convergence Insufficiency Treatment Trial Study G. Randomized clinical trial
of treatments for symptomatic convergence insufficiency in children.
Arch Ophthalmol. 2008;126(10):1336–49.
57. Argaud S, Verin M, Sauleau P, Grandjean D. Facial emotion recognition in
Parkinson's disease: a review and new hypotheses. Mov Disord. 2018;33(4):
554–67.
58. Scherer KR. Assessing the ability to recognize facial and vocal expressions of
emotion: construction and validation of the emotion recognition index. J
Nonverbal Behav. 2011;35(4):305–26.
59. Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend
J, McCarthy D, Wu SY. The Lens opacities classification system III. The
longitudinal study of cataract study group. Arch Ophthalmol.
1993;111(6):831–6.
60. Feizi S, Jafarinasab MR, Karimian F, Hasanpour H, Masudi A. Central and
peripheral corneal thickness measurement in normal and keratoconic eyes
using three corneal pachymeters. J Ophthalmic Vis Res. 2014;9(3):296–304.
61. Zhao D, Guallar E, Gajwani P, Swenor B, Crews J, Saaddine J, Mudie L,
Varadaraj V, Friedman DS, Group STGS. Optimizing Glaucoma screening in
high-risk population: design and 1-year findings of the screening to prevent
(SToP) Glaucoma study. Am J Ophthalmol. 2017;180:18–28.
62. Tanito M, Itai N, Dong J, Ohira A, Chihara E. Correlation between intraocular
pressure level and optic disc changes in high-tension glaucoma suspects.
Ophthalmology. 2003;110(5):915–21.
63. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, Boland TS,
Buznego C, Gira JP, Goldberg DF, et al. Dysfunctional tear syndrome: dry
eye disease and associated tear film disorders - new strategies for diagnosis
and treatment. Curr Opin Ophthalmol. 2017;27(Suppl 1):3–47.
64. Kwon OY, Kim SH, Kim JH, Kim MH, Ko MK. Schrimer test in Parkinson's
disease. J Korean Med Sci. 1994;9(3):239–42.
65. Zaman ML, Doughty MJ. Some methodological issues in the assessment of
the spontaneous eyeblink frequency in man. Ophthalmic Physiol Opt.
1997;17(5):421–32.
66. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S.
Detection of retinal changes in Parkinson's disease with spectral-domain
optical coherence tomography. Clin Ophthalmol. 2010;4:1427–32.
67. Mailankody P, Battu R, Khanna A, Lenka A, Yadav R, Pal PK. Optical
coherence tomography as a tool to evaluate retinal changes in Parkinson's
disease. Parkinsonism Relat Disord. 2015;21(10):1164–9.
68. Ucak T, Alagoz A, Cakir B, Celik E, Bozkurt E, Alagoz G. Analysis of the retinal
nerve fiber and ganglion cell - inner plexiform layer by optical coherence
tomography in Parkinson's patients. Parkinsonism Relat Disord. 2016;31:59–64.
69. de Carlo TE, Romano A, Waheed NK, Duker JS. A review of optical
coherence tomography angiography (OCTA). Int J Retina Vitreous. 2015;1:5.
70. Armstrong RA. Visual symptoms in Parkinson’s disease. Parkinson’s disease.
2011;2011:908306.
71. Sauerbier A, Ray Chaudhuri K. Parkinson’s disease and vision. Basal Ganglia.
2013;3(3):159–63.
72. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. National
eye Institute visual function questionnaire field test I: development of the
25-item National eye Institute visual function questionnaire. Arch
Ophthalmol. 2001;119(7):1050–8.
73. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with
systemic medications : recognition and management. Drugs. 2007;67(1):75–93.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Borm et al. BMC Neurology          (2019) 19:141 Page 9 of 9
